JP2022527081A5 - - Google Patents

Info

Publication number
JP2022527081A5
JP2022527081A5 JP2021557377A JP2021557377A JP2022527081A5 JP 2022527081 A5 JP2022527081 A5 JP 2022527081A5 JP 2021557377 A JP2021557377 A JP 2021557377A JP 2021557377 A JP2021557377 A JP 2021557377A JP 2022527081 A5 JP2022527081 A5 JP 2022527081A5
Authority
JP
Japan
Application number
JP2021557377A
Other languages
Japanese (ja)
Other versions
JPWO2020198531A5 (https=
JP2022527081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025069 external-priority patent/WO2020198531A2/en
Publication of JP2022527081A publication Critical patent/JP2022527081A/ja
Publication of JP2022527081A5 publication Critical patent/JP2022527081A5/ja
Publication of JPWO2020198531A5 publication Critical patent/JPWO2020198531A5/ja
Priority to JP2025024834A priority Critical patent/JP2025081512A/ja
Pending legal-status Critical Current

Links

JP2021557377A 2019-03-26 2020-03-26 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t) Pending JP2022527081A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025024834A JP2025081512A (ja) 2019-03-26 2025-02-19 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962824080P 2019-03-26 2019-03-26
US62/824,080 2019-03-26
US201962931103P 2019-11-05 2019-11-05
US62/931,103 2019-11-05
US202062969569P 2020-02-03 2020-02-03
US62/969,569 2020-02-03
PCT/US2020/025069 WO2020198531A2 (en) 2019-03-26 2020-03-26 Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025024834A Division JP2025081512A (ja) 2019-03-26 2025-02-19 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)

Publications (3)

Publication Number Publication Date
JP2022527081A JP2022527081A (ja) 2022-05-30
JP2022527081A5 true JP2022527081A5 (https=) 2023-04-03
JPWO2020198531A5 JPWO2020198531A5 (https=) 2023-04-03

Family

ID=72610137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557377A Pending JP2022527081A (ja) 2019-03-26 2020-03-26 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)
JP2025024834A Pending JP2025081512A (ja) 2019-03-26 2025-02-19 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025024834A Pending JP2025081512A (ja) 2019-03-26 2025-02-19 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)

Country Status (11)

Country Link
US (1) US20230312708A1 (https=)
EP (1) EP3953372A4 (https=)
JP (2) JP2022527081A (https=)
KR (1) KR20210143804A (https=)
CN (1) CN113710688A (https=)
AU (1) AU2020248448B2 (https=)
CA (1) CA3134465A1 (https=)
IL (1) IL286618A (https=)
MX (1) MX2021011494A (https=)
SG (1) SG11202110131SA (https=)
WO (1) WO2020198531A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415883A1 (en) * 2021-02-01 2024-12-19 The Regents Of The University Of California Treatment of neuroendocrine cancers
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
US12600801B2 (en) * 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
KR20250052305A (ko) * 2023-10-10 2025-04-18 서울대학교산학협력단 키메라 항원 수용체를 발현하는 자연 살해 세포를 이용한 종양 미세환경의 주피세포를 표적하는 항암 세포 치료 기법 및 치료 효능 평가를 위한 종양 미세환경 오가노이드 모델 제작 기술
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR102048855B1 (ko) * 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
AU2015343013B2 (en) * 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP6865688B2 (ja) * 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ror1に特異的な抗体およびキメラ抗原受容体
KR20190003938A (ko) * 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
EP3523331A1 (en) * 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
CN108424458A (zh) * 2017-02-13 2018-08-21 上海恒润达生生物科技有限公司 靶向ny-eso-1的嵌合抗原受体及其用途
MX2019015057A (es) * 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
BR112022009611A2 (pt) * 2019-11-18 2022-08-09 Univ California Anticorpos anti-ror-2 e métodos de uso

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022527081A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)